NCT04092725View on ClinicalTrials.gov

Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions

Pharmacokinetics

Interventions

DRUG

DAB

Single oral 150-mg dose of DAB on Day 1 AM.

DRUG

SCY-078 plus DAB

Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.

Trial Locations (1)

5000

CMAX, Adelaide